Menu
Not yet recruiting NCT07728370

RISE: Reducing Cancer and HIV Stigma Through Empowerment

No phase Interventional HIV Cervical Cancer Stigma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Neutral Video, Storytelling, Self disclosure, Combination.
Who it may be relevant to
Registry conditions: HIV, Cervical Cancer Stigma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This multilevel randomized behavioral study evaluates participant- and provider-level stigma-reduction interventions in Zambia. Participant-level intervention: Women living with cervical cancer and HIV (WLC+H ) are randomized in a 2×2 factorial design of storytelling versus neutral videos and storytelling versus neutral disclosure interventions to assess effects on quality of life, anxiety, and depressive symptoms. Provider-level intervention: Healthcare workers are randomized to storytelling or neutral videos to assess changes in stigma and compassion. The study also evaluates participant -reported stigma and satisfaction with care before and after implementation of the provider intervention.

Detailed description

People living with HIV face a substantially elevated risk of developing cancers due to compromised immunity. Among women, HIV significantly increases vulnerability to oncogenic human papillomavirus (HPV) infection, the primary cause of cervical cancer. This dual burden of cervical cancer and HIV disproportionately impacts low- and middle-income countries (LMICs), with Zambia exemplifying this crisis. Outcomes for affected individuals living with cervical cancer and HIV in LMICs are poor, with a one-year survival rate of just 65%. Addressing this intertwined public health challenge in LMICs is critical to advancing global efforts against cancer and HIV. This study uses a multilevel approach to address intersectional stigma at the patient and provider level.

In the participant -level component of the study, WLC+H (N=240) are randomly assigned to one of four conditions in a two (storytelling video vs. neutral video) by two (storytelling disclosure vs. neutral disclosure) factorial design. The primary outcome is quality of life (QOL), and the secondary outcomes are anxiety and depressive symptoms.

In the provider-level component of the study, healthcare workers (n=100) are randomly assigned to watch either storytelling or neutral videos. Outcomes (social and enacted stigma and compassion) among healthcare workers will be assessed pre-and post-intervention. An anonymous participant survey will also be administered to women living with cervical cancer and HIV (WLC+H) to compare outcomes between those treated before (control cohort, N=50) and after (intervention cohort, N=50) the implementation of the provider intervention. The anonymous patient survey will assess perceived stigma and satisfaction with care.

Interventions

  • Behavioral Neutral Video
    Participants in the control group will watch neutral videos and describe objective, non-emotional objects/events
  • Behavioral Storytelling
    The storytelling intervention group will watch the storytelling videos and then describe objective, non-emotional objects/events.
  • Behavioral Self disclosure
    Participants will watch neutral videos and then talk/write about their cancer/HIV-related experiences to themselves.
  • Behavioral Combination
    The combination group will watch the storytelling videos and then talk/write about their cancer/HIV-related experiences to themselves.
  • Behavioral Video
    Participants (healthcare workers) will watch storytelling videos in a group setting, followed by a facilitated discussion and role-playing to enhance empathy and understanding.
  • Behavioral Waitlist
    Participants will watch unrelated presentations in a group setting while on a waitlist. They will receive the intervention after completing the post-test.

Primary outcome measures

  • Quality of Life (Cancer) [Time frame: Baseline, immediately after the intervention, and 1-, 3-, 6-, and 12- month follow up]
  • Patient-level: Quality of Life (HIV) [Time frame: Baseline, immediately after the intervention, and 1-, 3-, 6-, and 12- month follow up]
Secondary outcome measures (2)
  • Patient-level: Depressive Symptoms [Time frame: Baseline, immediately after the intervention, and 1-, 3-, 6-, and 12- month follow up]
  • Patient-level: Anxiety Symptoms [Time frame: Baseline, immediately after the intervention, and 1-, 3-, 6-, and 12- month follow up]

Eligibility criteria

Inclusion criteria

Patient-level intervention

  • Women diagnosed with cervical cancer and HIV (stage I-IV)
  • Receiving cancer treatment at the Cancer Disease Hospital in Zambia
  • Aged 18 or above 4. Able to speak in English (the official language in Zambia) or one of four local languages (Bemba, Nyanja, Tonga, Lozi) for cultural inclusivity

Provider-level intervention

1\. Employment at the Cancer Disease Hospital in Lusaka, Zambia

Exclusion criteria

Patient-level intervention

1.Inability to provide informed consent and presence of a major mental health disorder (e.g., schizophrenia or bipolar disorder), as determined by participant records or self-report.

Provider-level intervention

1\. Inability to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Factorial
Masking
Double blind
Primary purpose
Supportive care

Study locations

United States · 1 center
  • UT MD Anderson — Houston

Identifiers

NCT: NCT07728370 · 2025-1064 · NCI-2026-04821

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗